DISCOUNT-OPTIONSSCHEIN - AMGEN | Real-time BOERSE MUENCHEN 16:45:25 23/05/2024 BST | ||
| 2.21 EUR | -0.90% |
|
| Current month | +127.55% | ||
| 1 month | +147.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 2.21 | -0.90% |
| 22/05/24 | 2.23 | -0.89% |
| 21/05/24 | 2.25 | +0.90% |
| 20/05/24 | 2.23 | +0.90% |
| 17/05/24 | 2.21 | 0.00% |
Real-time BOERSE MUENCHEN
Last update May 23, 2024 at 04:45 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC3BWA |
| ISIN | DE000HC3BWA4 |
| Date issued | 23/01/2023 |
| Strike | 270 $ |
| Maturity | 19/06/2024 (27 Days) |
| Parity | 10 : 1 |
| Emission price | 1 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.26 € |
|---|---|
| Lowest since issue | 0.31 € |
| Spread | 0.01 € |
| Spread % | 0.45% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
309.4
USD
Average target price
316.1
USD
Spread / Average Target
+2.15%
- Stock Market
- Certificates
- Certificat
